1Enzinger P C,Mayer R J. Esophageal cancer[J].New England Journal of Medicine,2003.2241-2252.
2Li J Y. Epidemiology of esophageal cancer in China[J].Natl Can-cer InstMonogr,1982.113-120.
3Gamliel Z,Krasna M J. Multimodality treatment of esophageal cancer[J].Surgical Clinics of North America,2005,(03):621-630.
4Pfaffl M W. A new mathematical model for relative quantification in real-time RT-PCR[J].Nucleic Acids Research,2001,(09):45.
5Ogawa R,Ishiguro H,Kuwabara Y. Expression profiling of micro-RNAs in human esophageal squamous cel carcinoma using RT-PCR[J].MEDICAL MOLECULAR MORPHOLOGY,2009,(02):102-109.
6Bueno M J,Perez de Castro I,Gomez de Cedron M. Ge-netic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1oncogene expression[J].Cancer Cel,2008,(06):496-506.
7Yuan Y,Zeng Z Y,Liu X H. MicroRNA-203 inhibits cel pro-liferation by repressing ΔNp63 expression in human esophageal squamous cel carcinoma[J].BMC Cancer,2011,(11):766-776.
8Lena A M,Shalom-Feuerstein R,Rivetti di Val Cervo P. miR-203 represses 'stemness' by repressing Delta Np63[J].Cel Death Differ,2008,(07):1187-1195.
9Schetter A J,Leung S Y,Sohn J J. MicroRNA expression profiles associated with prognosis and therapeuticoutcome in colon adenocarcinoma[J].Journal of the American Medical Association,2008,(04):425-436.
10Furuta M,Kozaki K I,Tanaka S. miR-124 and miR-203 are epigenetical y silenced tumor-suppressive microRNAs in-hepatocel ular carcinoma[J].Carcinogenesis,2010,(05):766-776.
3Andjelkovic T, Bankovic J, Stojsic J, et al. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. Transl Res,2011,157: 19-28.
4Karamitopoulou E, Zlobec I, Tornillo L, et al. Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia ( PanIN ). Pathology, 2010,42 : 229- 234.
5Kamada R, Nomura T, Anderson Cw,.et al. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J Biol Chem ,2011,286:252- 258.
6Scorah J, Dong MQ, Yates JR, et al. A conserved proliferating cell nuclear antigen-interacting protein sequence in Chkl is required for checkpoint function. J Biol Chem,2008,283 : 17250-17259.
7Li DQ, Pakala SB, Reddy SD, et al. Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAFI-proliferating cell nuclear antigen pathway. J Biol Chem, 2010, 285:10044-10052.
8Naryzhny SN, Lee H. Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer. FEBS Lett, 2010, 584:4292-4298.
9Hervouet E, Lalier L, Debien E, et al. Disruption of Dnmt1/PCNA/ UHRF1 interactions promotes tumorigenesis from human and mice glial ceils. PLoS One ,2010,5 : e11333.
10Hassan NM, Tada M, Shindoh M, et al. A multiple primary carcinoma consisting of leukoplakia and SCC : a case report with p53 mutation analysis. Anticancer Res ,2010,30:4773-4778.
